^
Association details:
| Biomarker: | CCDC6-RET fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | TY-1091 (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3419 / 29 - TY-1091, a highly selective and potent second-generation RET inhibitor, demonstrates superior antitumor activity in multiple RET-mutant models
Published date:
03/15/2023
Excerpt:
...TY-1091 demonstrated remarkable anti-tumor efficacy in a variety of xenograft models including Ba/F3 KIF5B-RET (wt), Ba/F3 KIF5B-RET (V804L), TT (thyroid cancer, RET C634W), and LC2/ad (NSCLC, CCDC6-RET).
